ALR Technologies Seeks FDA Approval For Insulin Dose Adjustment Feature for Better Diabetes Management
ALRT’s Algorithm Helps Physicians Optimize Treatment And Avoid Complications
(February 17, 2015 -- RICHMOND, VA) ALR Technologies Inc. (OTCQB: ALRT), a leading remote chronic care management and medical device company, is pleased to announce the submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for an innovative new addition to the Health-e-Connect system that will help busy physicians avoid common insulin dosing errors and remotely manage large populations of patients with diabetes without sacrificing the quality of care.
A first-in-class technology, the Insulin Dose Adjustment Consultation (IDAC) feature from ALRT uses an algorithm -- based on the guidelines of the American Association of Clinical Endocrinologists (AACE) -- to advise doctors instantly on the proper dose of insulin for each patient. The algorithm takes into account the current insulin dosage, the patient’s height and weight, and a review of blood glucose data from the patient’s glucose meter to efficiently deliver accurate dosing recommendations. With FDA 510(k) clearance, IDAC will become an important addition to the Health-e-Connect remote diabetes care management system.
On January 1, 2015, Medicare began reimbursing doctors for remote chronic care management practices, such as those enabled by the Health-e-Connect system. ALRT is actively negotiating with healthcare providers to capitalize on this new reimbursement while improving the quality of patient care.
“The proper dosing of insulin is one of the most important challenges in the clinical practice of diabetes,” said Bill Smith, President of ALR Technologies.
“According to the Institute for Safe Medication Practices (ISMP), insulin accounts for more than 10% of all drug dosing mistakes. Health-e-Connect with IDAC is an easy way for a prescribing clinician to optimize a patient’s insulin dose without an office visit while avoiding common errors.”
“We expect the IDAC feature will encourage the widespread adoption of intensive blood glucose management,” said Sidney Chan, Chief Executive Officer and Chairman of ALRT. “Research shows that intensive management can avoid significant micro-vascular complications and comorbidities resulting from poor blood glucose control. Besides these serious health consequences for patients, the poor outcomes produced by improper insulin dosing lead to significant, unnecessary healthcare costs.”
To view a video explaining the Insulin Dose Adjustment Consultation (IDAC) feature, click here: http://youtu.be/rRxEKUE4tkA
About ALR Technologies Inc.
ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with chronic diseases. ALRT has developed the FDA-cleared and HIPAA compliant Health-e-Connect System that collects data from blood glucose meters and uploads to a secure website. Trained Facilitators use the System to effect efficiency of care among patients, clinicians and caregivers to improve outcomes and assist health plans to optimize their quality goals. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data. More information about ALR Technologies, Inc. can be found at www.alrt.com.
For more information, email us at
This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words "estimate", "expect", "anticipate", "believe" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the Company's quarterly filings with the Securities Exchange Commission.